Advanced Biomimetic Sensors (ABS) is a woman-owned small business company founded in 2006. We strive to develop broken-through new generations of medical diagnostic and monitoring technologies targeting various diseases. We are passionate about the design, production, and marketing of life-saving high-performance medical device products that are more reliable, sensitive, affordable, and user-friendly.
OUR MANAGEMENT TEAM
Ellen T. Chen
ELLEN T. CHEN, Ph.D., is the founder and the CEO of ABS from 2006 to the present.
Dr. Chen has 27 years of experience in developing innovative nanobiomimetic reagent-free sensing and energy storage technology. Dr. Chen invented more than a dozen issued patents and a dozen pending patents. Dr. Chen led ABS received two National Innovation Awards, and a dozen national showcase awards.
ABS received several federal and state funded research grants. She published more than 70 peer-reviewed articles, three book chapters, and one college textbook. Dr. Chen gave more than 25 invited public presentations at national and international conferences. Before Dr. Chen founded ABS, she worked as a Principal Investigator (PI), and a Project Manager in conducting innovative research for 12 years at U.S. Food and Drug Administration (US FDA). Dr. Chen was a former Scientific Representative in Vitro Diagnostic medical devices from 1997 to 2001 for FDA. Her multiple-center (NIH, John Hopkins, and University of Maryland at Baltimore Medical System), clinical research projects in the Evaluation of Self-monitoring Blood Glucose (SMBG) Medical Devices on the Market, had won FDA’s highest research award. It cited: “For outstanding scientific expertise and leadership in addressing critical issues impacting the health of 16 million diabetes who use SMBG devices.” on June 11, 2001. Dr. Chen received 12 awards in medical device research and consultations to regulatory science at USFDA. Dr. Chen’s current research interests are in biomimetic reagent-free quantum sensors and energy storage devices. Dr. Chen mentored 4 Montgomery College students. Dr. Chen was a referee for several prestigious peer-reviewed journals in the fields of analytical chemistry and microsensors. Dr. Chen received her Ph.D. degree in analytical chemistry from Purdue University in 1994 and her master’s degree in analytical chemistry from Southern University in 1989. Dr. Chen is a member of IEEE, American Chemical Society, National Honorary Woman Chemical Society (IOTA SIGMA PI).
Peter T. Kissinger
PETER T. KISSINGER, Ph.D., is the Chief Advisory Board member in science at ABS.
Professor Kissinger was the founder of Bioanalytical Systems, Inc., which he led from 1974-2007, and was a full Professor of Chemistry at Purdue University, West Lafayette, Indiana from 1975- 2019.
Dr. Kissinger received a B.S. in Chemistry (1966) from Union College, Schenectady, N.Y., and a Ph.D. in Analytical Chemistry (1970) from the University of North Carolina in Chapel Hill. Before joining the faculty at Purdue in 1975, Kissinger was a Research Associate at the University of Kansas (1970-1972) and an Assistant Professor at Michigan State University (1972-1975). He founded BASi in 1974. Headquartered in West Lafayette, Indiana, BASi also has operations in multiple countries. Dr. Kissinger has published more than 230 scientific papers and is a Fellow of the American Association of Pharmaceutical Scientists and the American Association for the Advancement of Science. In 2005, he became the Chairman of Prosolia, which markets mass spectrometry innovations for life science, industrial, and homeland security applications. In 2007, he and Candice Kissinger founded Phlebotics, Inc., (www.phlebot.com), a medical device company focused on diagnostic information for intensive care medicine. In 2008, Professor Kissinger was the Associate Head of the Department of Chemistry at Purdue University, West Lafayette, Indiana. Professor Kissinger has retired from Purdue University in 2019.
SHOW-HONG DUH, Ph.D. was the Advisory Board Member in clinical pathology at ABS from 2006 to 2020.
Dr. Duh had more than 20 years of experience in medical device researches included the USFDA’s numerous clinical research projects.
Dr. Duh was an Associate Professor of Pathology at the University of Maryland School of Medicine since 2005. Dr. Duh received a B.S. degree in Pharmacy in 1970 in Taipei, Taiwan. Dr. Duh received an M.S. degree in Pharmaceutical Sciences in 1981 at North Dakota State University, Fargo, ND. Dr. Duh was Associate Director since 1989 in the Core/Clinical Chemistry Laboratory at the University of Maryland Medical Center. Dr. Duh received Joseph H. Roe Award from American Association for Clinical Chemistry Capital Section (2000).
Dr. Duh has retired from the University of Maryland Medical Systems in 2020.
Senior Application Engineer at Bruker Nano. John has dedicated his expertise and passion to helping and guiding small businesses, like help ABS, in many AFM innovative applications for more than a decade.
Kevin Bowen is President of Applied Robotics Systems and Porpoise Robotics, programs integrated with STEM education for middle and high school students. He continues to mentor small companies in the application of Systems Engineering to developing new technology.
Mr. Bowen retired from Raytheon Corporation as an Engineering Fellow and Chief Engineer for Maritime Vehicle Technology Development. He has performed Systems Engineering development on manned and unmanned Surface and Undersea Vehicles for 40 years. Mr. Bowen was a corporate Mentor under the DOD/Raytheon energy storage innovation Mentor-protégé program from 2010 to 2013 providing guidance to Dr. E. Chen at ABS.
Senior executive manager in product commercialization and marketing, has 40 years of experience in the electronics industry, having spent 30+ years at Hitachi medical in various executive roles. Tom is the President of Heiser Partners. Tom’s expertise in the medical and energy field helps ABS’s TNBC diagnostic product towards commercialization.
Ph.D., with more than 23 years of experience working in the pharmaceutical and preclinical molecular biology industry as a senior director at Intradigm Corporation and the co-founder and CSO in Bayside Biosciences. Dr. Xie has strong expertise in oncology, molecular and cell biology, and preclinical evaluations of gene therapy products. Dr. Xie invented 20 insured/pending patents.